53 results about "PTX3" patented technology

A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.

The invention provides applications of deoxyhypusine dioxygenase, namely, DOHH, or a fragment thereof in preparation of a reagent for diagnosis of anti-citrullinated protein antibody negative (ACPA-negative) rheumatoid arthritis (RA). In the method, a high-density protein chip is hybridized with RA serum to screen 35 proteins, which are candidate auto-antigens of the ACPA-negative RA. It is identified that four protein antigens, DOHH, DUSP11, PTX3 and PAGE5, have high sensitivity and specificity in ACPA-negative serum of the RA, wherein the four protein antigens are all novel auto-antigens. The method shows that the DOHH, DUSP11, PTX3 and PAGE5 can be used as diagnosis markers for the ACPA-negative RA.

The invention provides applications of Pentaxin related protein 3, namely, PTX3 or a fragment thereof, in preparation of a reagent for diagnosis of anti-citrullinated protein antibody negative (ACPA-negative) rheumatoid arthritis (RA). In the method, a high-density protein chip is hybridized with RA serum to screen 35 proteins, which are candidate autoantigens of the ACPA-negative RA. It is identified that four protein antigens, DOHH, DUSP11, PTX3 and PAGE5, have high sensitivity and specificity in ACPA-negative serum of the RA, wherein the four protein antigens are all novel auto-antigens. The method shows that the DOHH, DUSP11, PTX3 and PAGE5 can be used as diagnosis markers for the ACPA-negative RA.

A method of detecting a risk for or presence of asthma in a subject. The method comprises obtaining a biological sample comprising human airway smooth muscle cells from a subject and testing the biological sample for the presence of a pentraxin-3 (PTX3) polypeptide. The presence and / or quantity of PTX3 polypeptide in the biological sample correlates with the risk for or presence of asthma in the subject.

The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.

The invention relates to an amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma. It can be used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma.

The invention belongs to the technical field of immunoassay analysis and relates to a human pentraxin 3 (PTX3) magnetic particle chemiluminescence immunoassay quantitative detection kit and a preparation method thereof. The kit comprises a streptavidin-coated magnetic particle suspension, an alkaline phosphatase-labeled human pentraxin 3 monoclonal antibody, a biotin-labeled human pentraxin 3 monoclonal antibody and a human pentraxin 3 calibrator. Compared with an existing ELISA kit on the market at present, the kit provided by the invention has the advantages of wide detection range, higher repeatability and higher sensitivity.

To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.

The invention provides a preparing method and application of a human PTX3 recombinant protein. The method comprises the steps: constructing a eukaryocyte expression vector of the human PTX3 recombinant protein, knocking out apoptosis promoting factors in CHO-K1 cells, performing a calcium phosphate transfection program and performing enrichment and purifying of the human PTX3 recombinant protein. The vector capable of stably highly expressing protein in cells of mammal animals is constructed, and through antibiotic screening and improvement of conditions of a culture solution, an establishing yield is higher and expression is stable.

The invention discloses a method used for evaluating an immunomodulatory effect of lactobacillus acidophilus and an application of the method, and belongs to the field of biotechnology. According to the method provided by the invention, a dynamic change situation of immunity-related differentially expressed genes is detected, wherein the differentially expressed genes include up-regulated immunity-related genes CCL2, CCL20, IL1 alpha, IL1 beta, IL6ST, IL8, PTX3 and TNFRSF9 and a down-regulated immunity-related gene CXCR4. Through the method, the immunomodulatory effect of the lactobacillus acidophilus can be evaluated only by detecting nine immunity-related genes, and quick detection can be realized by utilizing Real Time PCR, so that the time is greatly shortened and the deficiency of existing evaluation of the immunomodulatory effect of the lactobacillus acidophilus is overcome; and the method is well verified in a mouse test and a Caco-2 cell.

Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival.

The present invention relates to a method and composition for treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4 / NFκB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.

The invention relates to the field of biological detection, in particular to application of IGSF1 protein as a cardiac function recovery marker. The invention provides application of protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction. The protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4, and is characterized in that the protein comprises one or more of the IGSF1, the LIMS1, the MPP1, the PTX3, the SLC2A3, the FERMT3, the ARPC1B, the IGHG1 The invention provides a novel serum marker, the expression level of the novel serum marker can predict heart failure patients with reduced ejection fraction and heart function recovery potential with high precision, and the change of the novel serum marker is earlier than the change of ejection fraction. According to the invention, a non-invasive standardized detection process based on a serum sample is established, all levels of medical institutions are adapted, and early and non-invasive prediction of the heart function recovery potential of the heart failure patient is realized.

A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.

The present invention relates to a novel PTX3 expression regulating agent, in which the expression regulating agent comprises microparticles, the microparticles comprise miRNA having a gene related to the expression of PTX3 as a target gene, and the expression regulating agent of PTX3 can regulate the expression of PTX3 using the miRNA from the microparticles; a prophylactic or therapeutic agent for vasculitis or skin sclerosis associated with rheumatoid arthritis and autoimmune diseases; the present invention relates to a method for improving vasculitis or skin sclerosis associated with rheumatoid arthritis and autoimmune diseases. The microparticles are preferably exosomes.

The invention belongs to the field of research of a streptococcus suis prevention and control technology, and provides a pVAX-PTX3 eukaryotic expression vector, a constructing method and an antibacterial application of PTX protein expressed by the eukaryotic expression vector in streptococcus suis 2. The gene ptx3 sequence of the PTX3 protein in the recombinant eukaryotic expression vector pVAX-PTX3 is as shown in SEQ ID NO. 1, and the PTX3 protein can be stably expressed in a tissue body. The sequence of the PTX3 is as shown in SEQ ID NO. 2, and the PTX3 protein can be used for preparing a biological preparation for preventing or treating streptococcus suis disease caused by streptococcus suis 2. A pVAX-PTX3 recombinant plasmid is strong in stability and can be stably and effectively expressed in the tissue body, and the PTX3 generated from expression has an antibacterial effect on the streptococcus suis 2; upon in vitro tests, in vivo tests on BALB / c mice and piglets verify that the PTX3 protein expressed by the pVAX-PTX3 has an antibacterial effect on the streptococcus suis 2; and by virtue of the pVAX-PTX3, a novel method for the clinical prevention and treatment of the streptococcus suis disease is established.

The invention relates to an in vitro method for determining whether a newborn patient has late-onset neonatal sepsis, which comprises determining the PTX-3 protein concentration in a biological sample previously obtained from said patient.

The invention discloses a vascular inflammation-related protein marker for auxiliary diagnosis or detection of cerebral hemorrhage and an application thereof. The protein marker is characterized in that the protein marker is a combination of KIM1 protein, IL6 protein, PTX3 protein and Gal-9 protein or KIM1 protein. The prepared kit for auxiliary diagnosis or detection of cerebral hemorrhage comprises RT-qPCR quantitative amplification primers of KIM1 transcriptome, IL6 transcriptome and PTX3 transcriptome. The advantage is that the detection kit based on detecting the transcriptome / protein expression level of KIM1 marker, IL6, PTX3, KIM1, Gal-9 combination marker and IL6, PTX3, and KIM1 combination marker can conveniently and quickly realize the detection of cerebral hemorrhage at the molecular level, and has high detection efficiency, high sensitivity and strong pertinence.

The invention discloses an application of a reagent for detecting the expression quantity of immunity related genes, a reagent kit and a head and neck cancer prognosis risk predicting device, and relates to the field of biomedicine. According to the application of the reagent for detecting the expression quantity of the immunity related genes to head and neck cancer prognosis risk disclosed by theinvention, the immunity related genes are selected from the following genes of: RFXAP, ULBP1, TMSB4Y, RBP4, LCNL1, CCR6, KLRK1, PTX3, MASP1, HRG, CCL22, OLR1, ROBO1, BTC, CHGB, DKK1, HBEGF, INHBB, PDGFA, AVPR2, IL20RA, RORB, TNFRSF18, TNFRSF25, TNFRSF4, SH3BP2 and ICOS; according to the expression quantity data of the immunity related genes, the head and neck cancer prognosis risk is predicted; and the reagent has good specificity and good sensitivity.

The invention provides application of recombinant collagen in preparation of a preparation for increasing the expression quantity of skin extracellular matrix homeostasis related genes. The amino acid sequence of the recombinant collagen is shown as SEQ ID NO: 1. The invention also provides a biomarker, wherein the biomarker is any one or a combination of at least two of skin extracellular matrix homeostasis related genes including CD44, COL16A1, COL23A1, COL27A1, COL4A1, COL6A3, COL6A6, COL7A1, DPT, ELN, HAS2, HAS3, IGFBP5, LAMB3, LAMB4, LAMC2, SLIT2, LUM, P4HA3, PDGFA, PTX3, SERPINE1, SPP1, TGFB2, TGFBR2 or VEGFA.

The invention provides a polypeptide for detecting an ACPA negative rheumatoid arthritis diagnosis marker and application of the polypeptide. The rheumatoid arthritis diagnostic marker is an anti-Pentaxin associated protein 3 antibody, and the amino acid sequence of the polypeptide, namely PTX3, is shown as SEQ ID NO. 4. The invention relates to an application of PTX3 in preparation of a reagent for diagnosing ACPA-negative rheumatoid arthritis. By detecting the rheumatoid arthritis diagnostic marker, the kit can be effectively used for detecting the rheumatoid arthritis, the detection rate is increased, and a basis is provided for preventing and treating the rheumatoid arthritis as soon as possible.

To provide a novel expression regulator for PTX3 that enables regulation of PTX3 expression using microparticle-derived miRNA.SOLUTION: The present invention provides an expression regulator for PTX3 that comprises microparticles, where the microparticles include miRNA that targets a gene related to PTX3 expression as a target gene. The present invention provides a prophylactic or therapeutic agent for rheumatoid arthritis, vasculitis associated with autoimmune disease, or sclerema. The present invention provides methods for improving rheumatoid arthritis, vasculitis associated with autoimmune disease, or sclerema. It is preferable that the microparticles are exosomes.SELECTED DRAWING: Figure 1

The invention discloses a method for screening a target gene of miR-29. The method uses a goat ovary DNA sequence as a template to amplify the 3' untranslated region (UTR) of a PTX3 gene under the condition of polymerase chain reaction (PCR) by using a PTX3 primer in a buffer environment in presence of Taq DNA polymerase, Mg<2+> and dNTPs; a dual-luciferase report system is constructed for detecting luciferase activity; the results show that the miR-29 reduces the luciferase activity, and the PTX3 is initially identified as the target gene of the miR-29; RT-qPCR and Western blot methods are used for verifying the impact of the miR-29 on the expression of the PTX3 gene at mRNA and protein levels. The results show that the miR-29 can inhibit the expression of the PTX3 gene at the mRNA and protein levels, so that the miR-29 is further determined to be bonded to PTX3'UTR, and the PTX3 is the target gene of the miR-29; therefore, a foundation is laid for study on the regulation of the miR-29 on ovary development and lambing traits of dairy goats.

The invention provides a group of polypeptides for detecting rheumatoid arthritis diagnostic markers and application thereof. The rheumatoid arthritis diagnostic marker is an anti-CCP antibody, an anti-PTX3 antibody and an anti-DUSP11 antibody, and polypeptides of the rheumatoid arthritis diagnostic marker are a CCP antigen protein, a PTX3 antigen protein and a DUSP11 antigen protein. The invention also discloses an application of the CCP antigen, the PTX3 antigen and the DUSP11 antigen protein in preparation of a reagent for diagnosing rheumatoid arthritis. Through combined detection of the three antibodies, the detection rate of rheumatoid arthritis can be effectively improved, missing detection is avoided, and a basis is provided for preventing and treating rheumatoid arthritis as soon as possible.

Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival.

The application provides application of recombinant collagen in preparation of a preparation for increasing expression of a skin extracellular matrix homeostasis related gene, and an amino acid sequence of the recombinant collagen comprises SEQ ID NO: 1. The application also provides a biomarker, and the biomarker is any one or a combination of at least two of skin extracellular matrix homeostasis related genes including CD44, COL16A1, COL23A1, COL27A1, COL4A1, COL6A3, COL6A6, COL7A1, DPT, ELN, HAS2, HAS3, IGFBP5, LAMB3, LAMB4, LAMC2, SLIT2, LUM, P4HA3, PDGFA, PTX3, SERPINE1, SPP1, TGFB2, TGFBR2 or VEGFA.

Disclosed is the use of Serum Amyloid P component (SAP) polypeptides for the treatment of Eurotiomycetes fungi infections, in particular for aspergillosis and invasive aspergillosis, alone or in combination with pentraxin-3 (PTX3) polypeptides.

The invention belongs to the technical field of molecular biology, and relates to a construction method and application of a mouse mammary tissue miRNA overexpression model. A miRNA exogenous reagent-bta-16b-agomiR is injected through mammary tissue by adopting a microsyringe, a mouse is killed 48 hours after injection, RNA is extracted from the mammary tissue by using chloroform, reverse transcription is performed to obtain cDNA, and the overexpression effect of the bta-16b-agomiR and the mRNA expression levels of PGLYRP1 and PTX3 are detected by using fluorescent quantitative PCR; and the mammary tissue is subjected to HE staining and PGLYRP1 and PTX3 immunohistochemical tests. The method disclosed by the invention can be widely applied to overexpression of miRNA in the mouse mammary tissue and related research of the miRNA in living tissue, and a model basis is provided for tests of pathology mechanisms, immune mechanisms and the like of mastitis related diseases.